Precigen (PGEN) Long-Term Debt Repayments (2012 - 2023)
Precigen (PGEN) reported Long-Term Debt Repayments of $13.9 million for Q2 2023, up 12193.81% year-over-year from N/an in Q2 2022, and down 52.63% quarter-over-quarter from $29.3 million in Q1 2023.
Precigen (PGEN) Long-Term Debt Repayments (2012 - 2023) Analysis & Trends
Precigen (PGEN) has 12 years of Long-Term Debt Repayments data on file, last reported at $13.9 million in Q2 2023.
- Long-Term Debt Repayments for Q2 2023 came in at $13.9 million, up 12193.81% year-over-year; the trailing twelve-month figure through Mar 2024 was $13.9 million (down 92.47% YoY), and the FY2023 annual result was $43.2 million, down 72.17% from the prior year.
- Long-Term Debt Repayments retreated to $13.9 million in Q2 2023 per PGEN's latest filing, from $29.3 million in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $115.7 million in Q3 2022 and troughed at $113000.0 in Q2 2022.
- A 5-year average of $11.1 million and a median of $137500.0 in 2019 frame the typical range for Long-Term Debt Repayments.
- The sharpest annual moves came in 2019 and 2022: Long-Term Debt Repayments slipped 29.9% in 2019, then jumped 98817.95% in 2022.
- A 5-year view of Long-Term Debt Repayments shows it stood at $154000.0 in 2019, then retreated by 22.08% to $120000.0 in 2020, then declined by 4.17% to $115000.0 in 2021, then soared by 34058.26% to $39.3 million in 2022, then sank by 64.64% to $13.9 million in 2023.
- Business Quant data shows PGEN's Long-Term Debt Repayments at $13.9 million in Q2 2023, $29.3 million in Q1 2023, and $39.3 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | LT Debt Repayment (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 13.89 Mn |
| Jun 30, 2023 | 13.89 Mn |
| Mar 31, 2023 | 29.33 Mn |
| Mar 31, 2023 | 29.33 Mn |
| Dec 31, 2022 | 39.28 Mn |
| Dec 31, 2022 | 39.28 Mn |
| Sep 30, 2022 | 115.73 Mn |
| Sep 30, 2022 | 115.73 Mn |
| Jun 30, 2022 | 113,000.00 |
| Jun 30, 2022 | 113,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | 117,000.00 |
| Sep 30, 2021 | 117,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Mar 31, 2021 | 116,000.00 |
| Mar 31, 2021 | 116,000.00 |